-
Mashup Score: 2
e19513 Background: Patients (Pts) with hematologic malignancies (HM) are at greater risk of severe morbidity and mortality caused by COVID19 and show a lower response to the two-dose COVID19 mRNA vaccine series. The primary vaccine series now includes a third dose of the COVID19 vaccine (3V) for immunocompromised Pts. The objective of this study was to explore the characteristics of HM patients who had no change in SARS-CoV-2 spike protein titer levels post 3V (-/-) to gain a better understanding of the drivers of serostatus. Methods: This retrospective cohort study analyzed Pt data on SARS-CoV-2 spike IgG antibody titers pre- and post- 3V across the healthcare system. This study included 268 fully vaccinated HM Pts diagnosed with HM between October 31, 2019 and January 31, 2022 and had a negative serostatus prior to 3V. Post 3V titers were obtained 21 days after 3V. Demographics, association between characteristics and seroconversion status, and odds ratios were all assessed (table).
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
1530 Background: In a prior analysis, we identified 525 pts with newly diagnosed NSCLC 4 harboring AOD in the ICD. Of these, 141 were treated prior to the reporting of AOD with chemotherapy (C), immune checkpoint inhibitor (ICI), or both. This report details the clinical outcomes of these 141 compared to the 384 treated after AOD reported. Methods: Real world data (RWD) were obtained from a curated ICD for pts with NSCLC 4 diagnosed 1/1/2018-12/31/2020 with cutoff of data 3/31/2021. Pts with EGFR, ALK, ROS1, BRAF, MET, RET, HER2, and NTRK were included if their treatment record were captured. Also included were demographics, ECOG score, date of first report of AOD and dates of initiations of first and any second line of therapy and date of apparent death (AD). Outcome measures were time to next treatment or apparent death (TTNT) and apparent survival (AS) (ICD model does not allow date of death per HIPAA de-identified Expert Determination). Descriptive statistics were used with Kaplan-
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 10 month(s) ago
AuthorsChristine HoRoswell Park Comprehensive Cancer Center, Buffalo, NYChristine Ho, Paul K. Wallace, Kristopher Attwood, Sarah Parker, Hemn Mohammadpour, Megan Herr, George Chen, Joseph Tario, Philip L. McCarthy, Jens HillengassOrganizationsRoswell Park Comprehensive Cancer Center, Buffalo, NY, Roswell Park Comprehensive Cancer Center, Transplant and Cellular Therapy Program, Department of…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2The woman behind AstraZeneca’s cancer winning streak - 11 month(s) ago
“Seeing a drug emerge is one of the most exciting things that you can do,” said AstraZeneca’s Susan Galbraith. “And then seeing that other people start to see it in that way. That’s a very exciting moment.” #ASCO23
Source: STATCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 6Healio Disruptive Innovators - 11 month(s) ago
Saturday June 3 · 6:00 PM – 7:30 PM Central Daylight Time (CDT). The TAP Hyatt Regency McCormick Place 2233 S Martin Luther King DrChicago, IL 60616 Join us as we celebrate the movers, shakers and industry-name-makers at this prestigious awards ceremony hosted by Healio | HemOnc Today. The Disruptive Innovators awards will span across nine…
Source: www.healio.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 12 month(s) ago
AuthorsJuan DuShanghai Changzheng Hospital, Shanghai, Shanghai, ChinaJuan Du, Wei-Jun Fu, Hua Jiang, Baoxia Dong, Li Gao, Li Liu, Jian Ge, Aili He, Lu Li, Jing Lu, Xiequn Chen, Jia Liu, Qi Zhang, Jiaping He, Lianjun Shen, Lihong Weng, Hua Zhang, Wei Cao, Wenling LiOrganizationsShanghai Changzheng Hospital, Shanghai, Shanghai, China, Shanghai Changzheng Hospital, Shanghai, China, Xijing Hospital,…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 12 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
AuthorsChristine HoRoswell Park Comprehensive Cancer Center, Buffalo, NYChristine Ho, Paul K. Wallace, Kristopher Attwood, Sarah Parker, Hemn Mohammadpour, Megan Herr, George Chen, Joseph Tario, Philip L. McCarthy, Jens HillengassOrganizationsRoswell Park Comprehensive Cancer Center, Buffalo, NY, Roswell Park Comprehensive Cancer Center, Transplant and Cellular Therapy Program, Department of…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0CEACAM5: Safety and Efficacy Outcome in Long-term Treatment with SAR408701 in Pts with NSQ NSCLC Prof Charles Ricordel - 1 year(s) ago
CEACAM5: Safety and Efficacy Outcome in Long-term Treatment with SAR408701 in Pts with NSQ NSCLC Prof Charles Ricordel By Professor Charles Ricordel As many of you may know, antibody drug conjugates are generating a lot of hype right now in the oncology field, and RFT-Sign is a novel antibody drug conjugate that sel…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0DCISionRT: Assessing Breast Cancer Adjuvant Endocrine Therapy After BCS Chirag Shah MD - 1 year(s) ago
DCISionRT: Assessing Breast Cancer Adjuvant Endocrine Therapy After BCS Chirag Shah MD By Chirag Shah, MD So this study was an analysis of 926 patients who had undergone breast conserving surgery, with or without radiation therapy and with or without endocrine therapy. They were diagnosed with ductal carcinoma in si…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Characteristics of Pts w/ hematologic malignancies w/o seroconversion post-#COVID19 3rd vaccine dosing (3V): Real-world data from large midwestern healthcare system [Jun 2, 2022] Hallmeyer et al. @JimW9200 Abstract e19513 #ASCO22 https://t.co/22Q2IGyWHE #COVID19Vaccine #IDonc https://t.co/YwhB2jYEUC